Researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) are set to unveil a series of groundbreaking studies at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. These investigations span a broad spectrum of cancer research, covering novel drug access programs, molecular insights into specific cancers, advancements in targeted therapies, and critical evaluations of clinical trial demographics. The collective findings advance the frontier of oncology by tackling treatment delays, uncovering distinct cancer biology in younger populations, and identifying persistent disparities in medical research representation.
One of the most transformative initiatives presented involves an innovative hospital-based oral cancer drug repository program. Spearheaded by pharmacists at OSUCCC – James, this program allocates unused oral cancer medications, donated by patients, directly to other patients in urgent need of these drugs. This redistribution effectively circumvents prolonged delays often associated with insurance approvals, pharmacy delivery lag times, and prohibitive costs. By enabling pharmacists to dispense medications at point-of-care—either in clinics or at bedside for inpatients—the program drastically shortens the wait for vital oral chemotherapy drugs from typically over two weeks down to approximately six days. Notably, from February 2021 through September 2025, the repository returned more than $4 million worth of oral medications back into patient care. This innovative model not only decreases supply constraints and financial barriers but also sustains treatment adherence during vulnerable windows when conventional drug access pathways falter.
Meanwhile, oncologists investigating colorectal cancer have revealed compelling molecular distinctions in tumors occurring in younger adults compared to their late-onset counterparts. Through advanced genomic analyses, OSUCCC – James researchers identified that early-onset colorectal cancers manifest unique interactions with the nervous system, notably promoting inflammatory cascades and altering lipid metabolism pathways. This biologically distinct phenotype is further underscored by the discovery of an “aging clock” composed of 11 genes, whose expression patterns accelerate cellular aging in colon tissue under environmental stresses. This molecular signature holds promise for the development of minimally invasive blood-based assays capable of screening younger adults long before conventional colonoscopies are recommended. Such precision oncology tools could revolutionize early detection and prevention strategies, addressing the troubling rise in colorectal cancer incidence among younger demographics.
In lung cancer therapeutics, OSUCCC – James investigators presented encouraging preliminary results from a phase Ib clinical trial combining osimertinib, a third-generation EGFR tyrosine kinase inhibitor, with the experimental agent tegavivint. This trial targets metastatic non-small cell lung cancers harboring EGFR mutations, a subset frequently developing resistance to monotherapy. The combination therapy demonstrated a robust objective response rate of 73%, including some patients achieving radiographic complete responses with no detectable disease. Median progression-free survival extended to 20.6 months, a promising improvement over historical osimertinib monotherapy data. Importantly, the regimen was well tolerated without unexpected toxicities, suggesting that dual targeting may enhance therapeutic outcomes without substantially escalating adverse events. Although these results are preliminary, they pave the way for larger trials to confirm whether this combination can circumvent resistance mechanisms and prolong durable remissions in EGFR-mutant lung cancer.
Despite advances in oncology research globalization, disparities in clinical trial participation remain stubbornly entrenched. A comprehensive meta-analysis of nearly 1,400 cancer clinical trials spanning 1995 to 2025 revealed increased international trial sites, especially across Asia, and more consistent reporting of race and ethnicity. However, Black and Hispanic patient enrollment lagged behind, with some evidence of declining representation over time. These findings underscore that merely expanding trial reach worldwide does not equate to equitable inclusion of diverse patient populations. OSUCCC – James researchers emphasize the necessity of enhanced recruitment strategies, standardized demographic reporting, and innovative tracking systems to ensure that clinical data reflect the heterogeneity of the patient populations most affected by cancer. Addressing these gaps is imperative for developing inclusive therapies and mitigating health disparities.
In breast cancer research, an extensive analysis of nearly 142,000 patients investigated the benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC), a subtype often overshadowed by ductal breast cancer studies. The data revealed nuanced benefits contingent on Oncotype DX recurrence scores and menopausal status. Patients with high recurrence scores, particularly postmenopausal women, exhibited the most pronounced survival advantages with chemotherapy. Conversely, those with low scores derived minimal benefit, and younger premenopausal patients showed limited chemotherapy impact within intermediate-risk subgroups. This refined stratification offers clinicians more precise tools for individualized treatment planning, potentially sparing low-risk patients from unnecessary chemotherapy toxicities. Nevertheless, researchers advocate for the identification of additional biomarkers, as current genomic assays do not fully capture the complexity of treatment response in ILC.
Genetic screening for Lynch syndrome, an inherited cancer predisposition condition, also saw compelling reevaluation. By analyzing nearly 250,000 cancer patients, researchers found that standard testing relying exclusively on tumors exhibiting microsatellite instability (MSI) missed a significant proportion of Lynch syndrome cases—25% in colorectal cancer and 44% in endometrial cancer. This reduction in screening sensitivity highlights the inadequacy of restrictive testing algorithms, risking missed opportunities for early intervention and familial risk assessment. The data advocate for expanded genetic testing protocols encompassing broader tumor phenotypes and germline analyses. Such approaches could facilitate more comprehensive identification of high-risk individuals, enabling timely surveillance and preventive strategies that ultimately reduce cancer incidence and mortality in affected families.
Attention to breast cancer treatment patterns among younger women illuminated a discordance between recurrence risk scores and chemotherapy administration. A cohort study of over 6,000 women under 50 years old revealed that despite low recurrence test results, many patients still underwent chemotherapy, especially when lymph node involvement or tumor size increased. This indicates that oncologists integrate multiple clinical and pathological factors in decision-making beyond singular genomic scores. The findings expose ongoing uncertainty regarding chemotherapy’s benefit in young breast cancer patients with ostensibly low-risk disease profiles. Consequently, this calls for intensified research to clarify chemotherapy’s precise role and to develop predictive models facilitating truly personalized therapeutic regimens that maximize efficacy and reduce overtreatment.
Intriguing epidemiological insights emerged regarding the role of aspirin in endometrial cancer survival. Retrospective analysis of 765 patients demonstrated an association between aspirin use at diagnosis and decreased cancer-specific mortality, even after adjusting for confounding variables such as age, stage, and treatment modalities. While causality cannot be inferred from observational data alone, this correlation generates a compelling rationale for mechanistic studies and prospective clinical trials to evaluate aspirin as a potential adjuvant agent. Given aspirin’s anti-inflammatory and anti-platelet properties, the drug’s impact on tumor microenvironment, angiogenesis, and immune modulation merits rigorous exploration within gynecologic oncology.
Among ongoing clinical trials, a notable study targets MET amplification, a relatively rare but oncogenic driver alteration occurring in approximately 3-4% of non-small cell lung cancers. This trial evaluates amivantamab hyaluronidase, a bispecific antibody that concurrently inhibits EGFR and MET signaling pathways, aiming to overcome resistance in advanced disease. The study not only assesses tumor response and progression-free survival but also explores the utility of liquid biopsies to detect MET amplification. The success of this approach could epitomize the precision medicine paradigm, whereby treatment is intricately matched to tumor genetics, improving outcomes for subsets of patients with previously limited options.
The research excellence at OSUCCC – James has been further recognized through prestigious honors presented at the ASCO conference. Dr. Raphael E. Pollock, director emeritus, was inducted into the OncLive Giants of Cancer Care®, acknowledging his impactful contributions to surgical oncology. Additionally, early-career investigators Drs. Lingbin Meng and Mateus Trinconi Cunha received generous Conquer Cancer Foundation awards to support their pioneering clinical research. These accolades underscore the institution’s commitment to cultivating innovation and leadership across oncology disciplines.
Through a constellation of strategic studies and clinical trials, OSUCCC – James continues to elevate cancer care by bridging scientific discovery with patient-centered innovations. Their multifaceted efforts in enhancing drug accessibility, elucidating cancer biology unique to demographic subgroups, refining therapeutic combinations, and advocating for diversity in clinical research collectively herald a new era of oncology—one focused on equitable, precise, and timely interventions that can ultimately transform patient outcomes worldwide.
Subject of Research: Cancer research spanning drug access, molecular oncology, targeted therapies, and clinical trial diversity.
Article Title: Ohio State Researchers Showcase Innovative Cancer Studies at ASCO 2026
News Publication Date: 2026
Web References:
OSUCCC – James official website: http://cancer.osu.edu/asco
ASCO abstracts portal: https://www.asco.org/abstracts-presentations
Keywords:
Cancer research, oral cancer drugs, colorectal cancer biology, EGFR-mutant lung cancer, clinical trial diversity, invasive lobular carcinoma, Lynch syndrome, breast cancer chemotherapy, aspirin in endometrial cancer, MET amplification, targeted therapy, OSUCCC – James, ASCO 2026
Tags: breast cancer treatment advancementscancer drug donation programclinical trial access disparitiesinsurance barriers in cancer treatmentlung cancer targeted therapiesLynch syndrome screening in oncologymolecular cancer research insightsoncology clinical trial demographic evaluationoral chemotherapy drug accesspediatric and young adult cancer biologypharmacy-led cancer drug redistributionreducing treatment delays in cancer care
